Heparanase-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Heparanase-1 (HPSE; UniProt Q9Y251), expressed in HEK293 cells. Suitable for heparan sulfate cleavage assays, inhibitor IC50 determination, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Heparanase1

In stock

SKU
REC-Heparanase1
$498.00

Target Overview

Heparanase-1 (HPSE; UniProt Q9Y251) is a mammalian endo-β-glucuronidase that cleaves heparan sulfate side chains from heparan sulfate proteoglycans (HSPGs) at specific glucuronic acid–N-sulfo glucosamine linkages. The full-length precursor spans 543 amino acids and undergoes proteolytic processing into an 8 kDa and a 50 kDa subunit; the active enzyme is a heterodimer of these two processed forms. This recombinant is expressed in HEK293 cells, providing mammalian glycosylation patterns that closely reflect those of the native human enzyme — a relevant consideration for substrate recognition studies and inhibitor profiling where glycoform-dependent activity differences have been documented. The enzyme displays a pronounced pH optimum in the acidic range, consistent with its lysosomal localisation and its activation in the acidic microenvironments encountered during tumour invasion and inflammatory processes. This pH-activity relationship makes the recombinant particularly tractable for controlled in-vitro kinetic experiments where buffer pH can be systematically varied. In the laboratory, this recombinant protein is used primarily in three experimental contexts: (1) enzymatic activity assays against heparan sulfate or defined sulfated oligosaccharide substrates, enabling quantification of cleavage rate and pH dependence; (2) inhibitor IC50 determinations for small molecules and heparin mimetics targeting the HPSE active site; and (3) antibody validation, where the recombinant serves as a defined positive control antigen for immunoblotting and immunoassay standardisation. Researchers requiring a validated detection reagent for Western blot or IHC confirmation of recombinant identity can pair this product with the Triple Point Biologics matched antibody (SKU: RP-Heparanase1).

Background

Heparanase-1 (HPSE) is the sole mammalian endoglycosidase with demonstrated activity toward heparan sulfate, positioning it as a central regulator of extracellular matrix (ECM) remodelling. By cleaving heparan sulfate chains on syndecans, glypicans, and perlecan, the enzyme releases a broad array of growth factors and chemokines sequestered within the ECM, including VEGF, FGF, and HGF — each of which mediates downstream signalling cascades relevant to cell proliferation, migration, and angiogenesis. Beyond its enzymatic role, HPSE has been shown to promote AKT1 phosphorylation through lipid raft-mediated mechanisms independently of its catalytic activity, suggesting multifunctional biology that extends beyond simple matrix degradation. HPSE has been studied as a research target across a number of disease-relevant contexts. In oncology research, it has been characterised in models of metastasis and tumour microenvironment remodelling; Zhu et al. (2026, PMID: 42275439) investigated HPSE-loaded extracellular vesicles in a colorectal tumour context, demonstrating how HPSE-mediated ECM degradation can influence immune cell infiltration and antitumour responses in preclinical models. The structural basis of substrate recognition has also attracted significant attention: Pennacchio et al. (2026, PMID: 42208670) examined how pH and heparan sulfate sulfation patterns govern human heparanase conformation, stability, and substrate selectivity — findings directly applicable to the design of in-vitro activity assays using this recombinant. In the context of inflammation, HPSE activity correlates with heparan sulfate shedding from endothelial and epithelial surfaces; Sallee et al. (2026, PMID: 42147147) characterised plasma heparan sulfate structural variation in paediatric acute respiratory distress syndrome, reflecting how HPSE-driven HS remodelling is investigated as a marker of endothelial injury in inflammatory disease research. The enzyme has additionally been identified in serum proteomics studies of neurodevelopmental conditions (Popov et al., 2025, PMID: 42147996) and in network-based target analysis of metabolic disease models (Bai et al., 2026, PMID: 42149890), illustrating the breadth of basic research contexts in which HPSE is examined as a molecular target. For inhibitor discovery, the well-defined active-site architecture of HPSE — a TIM-barrel fold with two catalytic glutamate residues — makes this recombinant a reproducible enzyme source for fluorescence-based or HPLC-coupled substrate cleavage assays. The HEK293 expression system preserves mammalian post-translational modifications relevant to these structure–activity studies.

Applications

  • Heparan sulfate substrate cleavage activity assay (fluorometric or HPLC-coupled)
  • Inhibitor IC50 determination against small-molecule or heparin-mimetic HPSE inhibitors
  • pH-dependent kinetic profiling of HPSE endoglycosidase activity
  • Antibody validation positive control for Western blot (pairs with TPB RP-Heparanase1)
  • Antibody validation positive control for IHC/IHC-P antigen standardisation
  • ECM remodelling mechanistic studies: HS chain release and growth factor liberation assays
  • Substrate specificity mapping using defined sulfated oligosaccharide libraries
  • Binding and biophysical characterisation (SPR, ITC) with heparan sulfate or inhibitor candidates

References

  1. Zhu S et al. Heparanase-Loaded CAR T Extracellular Vesicles Remodel the Colorectal Tumour Microenvironment and Boost T Cell Antitumor Immunity. J Extracell Vesicles. 2026. doi:10.1002/jev2.70310. PMID: 42275439
  2. Pennacchio A et al. How pH and sulfation shape human heparanase structure, stability, and substrate recognition. Arch Biochem Biophys. 2026. doi:10.1016/j.abb.2026.110879. PMID: 42208670
  3. Sallee CJ et al. Plasma Heparan Sulfate Structural Variation and Phenotypic Heterogeneity in Pediatric Acute Respiratory Distress Syndrome. Res Sq. 2026. doi:10.21203/rs.3.rs-9337695/v1. PMID: 42147147
  4. Popov TN et al. Identification of Serum Proteome in Children with Autism Spectrum Disorder. Balkan J Med Genet. 2025. doi:10.2478/bjmg-2025-00023. PMID: 42147996
  5. Bai L et al. Network toxicology and bioinformatics analysis predict potential molecular targets and mechanisms by which sevoflurane and propofol influence type 2 diabetes mellitus. PLoS One. 2026. doi:10.1371/journal.pone.0349565. PMID: 42149890

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight bands should I expect from recombinant Heparanase-1 on SDS-PAGE or Western blot?

REC-Heparanase1 is expressed as the full-length 543 aa precursor in HEK293 cells and undergoes proteolytic processing into an 8 kDa and a 50 kDa subunit — the two forms that associate non-covalently to constitute the active heterodimer. Under reducing SDS-PAGE conditions you should see a dominant band at ~50 kDa and, depending on loading amount and staining sensitivity, a secondary band near 8 kDa. The full-length precursor (~65 kDa with glycosylation) may also appear as a minor species. Purity is >90% by SDS-PAGE, so these are the bands you should budget for when interpreting blots.

What is the active form of recombinant Heparanase-1 and how does the proteolytic processing work?

The native human enzyme (UniProt Q9Y251) is translated as a 543 aa inactive precursor that is cleaved to remove a linker segment, yielding an 8 kDa N-terminal subunit and a 50 kDa C-terminal subunit. These two subunits re-associate as a non-covalent heterodimer, which is the catalytically active form. REC-Heparanase1 is produced in HEK293 cells and supplied in the processed, active heterodimeric state. Because HEK293 cells recapitulate mammalian glycosylation, the glycoform profile closely mirrors native HPSE — a relevant advantage when glycoform-dependent substrate recognition or inhibitor binding is part of your experimental rationale.

What substrate does recombinant Heparanase-1 cleave and at what cleavage site?

Heparanase-1 is a mammalian endo-β-glucuronidase that cleaves heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs) at specific glucuronic acid–N-sulfo glucosamine linkages. For in vitro activity assays, biotinylated or fluorescently labeled heparan sulfate substrates (e.g., HS oligosaccharide-based FRET substrates) are most commonly used. Standard solid-phase HS degradation assays using 35S-labeled HSPGs or commercially available fluorescent HS substrates at 0.5–5 µg/reaction also work well. Activity is pH-dependent — assays run optimally in the pH 5.0–6.0 range, consistent with the enzyme's lysosomal origin.

What buffer and pH conditions should I use for a Heparanase-1 activity assay in vitro?

REC-Heparanase1 has a pronounced pH optimum in the acidic range, typically pH 5.0–6.0, consistent with its lysosomal localisation. For activity assays, a standard buffer is 50 mM sodium acetate or MES, pH 5.4, supplemented with 1–5 mM DTT to maintain reducing conditions. The storage buffer for this recombinant is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — dilute the enzyme into your assay buffer immediately before use. Avoid extended incubation at neutral or alkaline pH, as enzymatic activity drops significantly outside the pH 4.5–6.5 window.

What starting concentration of recombinant Heparanase-1 should I use for an IC50 inhibitor profiling assay?

For IC50 determinations, begin with 0.1–1 µg/mL of REC-Heparanase1 in your assay buffer (pH 5.4). This concentration range typically gives a robust, linear signal with fluorescent HS substrates at 10–50 µg/mL substrate concentration, while remaining within the dynamic range needed to detect inhibition across a broad compound concentration series. Run a substrate saturation curve first to confirm you are not substrate-limited. Because mammalian glycoforms can influence inhibitor binding affinity relative to bacterially expressed enzyme, the HEK293-derived protein here is the preferred choice for inhibitor profiling intended to translate to cellular or in vivo settings.

Can I use REC-Heparanase1 as a positive control for Western blot with the matched anti-Heparanase-1 antibody?

Yes — this is one of the most straightforward use cases. REC-Heparanase1 is specifically paired with RP-Heparanase1, the rabbit polyclonal antibody available at /anti-heparanase-1-rabbit-polyclonal-antibody. The antibody has been validated for Western blot detection of the processed 50 kDa subunit, which is the dominant species in this recombinant preparation. Load 20–50 ng of REC-Heparanase1 per lane alongside your cell or tissue lysates; this quantity reliably produces a clear 50 kDa signal without saturating the band. Using the matched pair also confirms antibody lot-to-lot consistency — a practical advantage for long-running studies.

How much recombinant Heparanase-1 should I load for a Western blot positive control lane?

For a standard chemiluminescent Western blot using RP-Heparanase1, load 20–50 ng of REC-Heparanase1 per lane. At 20 ng you should see a clean ~50 kDa band with most standard HRP-conjugated secondary antibodies at 1:5,000–1:10,000 dilution. If you are running a less sensitive detection method, increase to 50 ng. Avoid loading more than 100 ng — above this threshold the band can smear or bleed into adjacent sample lanes. The 8 kDa subunit may require higher loading (100–200 ng) and a higher-percentage gel (15–18%) for reliable detection.

How should I store and handle REC-Heparanase1 to maintain enzymatic activity long-term?

REC-Heparanase1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at -20°C in single-use aliquots. Repeated freeze-thaw cycles cause measurable loss of specific activity — aliquot upon first receipt if the lot was shipped as a single vial. For short-term working use (1–3 days), the enzyme is stable at 4°C. When diluting for assay, use a carrier protein such as 0.1% BSA in your assay buffer to reduce adsorptive losses at low protein concentrations. Endotoxin is <0.1 EU/µg by LAL assay, making this preparation compatible with cell-based and primary culture experiments.

Validation imagery coming soon

Western blot validation figures for REC-Heparanase1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →